Pharmaceuticals

SINOTHERAPEUTICS

SINOTHERAPEUTICS released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 94.55 M, actual EPS CNY 0.04

SINOTHERAPEUTICS FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

SINOTHERAPEUTICS to Release FY2025 Earnings on April 30, 2026 Pre-Market BJT

SINOTHERAPEUTICS released FY2025 Annual Earnings on February 27 Pre-Market (BJT), actual revenue CNY 446.57 M, actual EPS CNY 0.11

SINOTHERAPEUTICS released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 115.1 M, actual EPS CNY -0.0435

SINOTHERAPEUTICS FY2025 Q3 Earnings Release on October 31, 2025, After-Market (BJT)

SINOTHERAPEUTICS released FY2025 9 Months Earnings on October 14 After-Market BJT, actual revenue CNY 331.46 M, actual EPS CNY 0.1398

SINOTHERAPEUTICS released FY2025 Q3 earnings on October 14 After-Market BJT, actual revenue CNY 111.86 M, actual EPS CNY 0.0398

SINOTHERAPEUTICS released FY2025 Q2 earnings on August 22 After-Market BJT, actual revenue CNY 110.68 M, actual EPS CNY 0.05

SINOTHERAPEUTICS released FY2025 Semi-Annual earnings on August 22 After-Market BJT, actual revenue CNY 219.61 M, actual EPS CNY 0.1

SINOTHERAPEUTICS to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Subsidiary of Xuantai Medicine Receives Hungary's GMP Certification

Qihuo Entrepreneurship Plans to Reduce Holdings in Xuantai Pharmaceutical by No More Than 1.5441%

XuanTai Medicine's Enzalutamide Tablets Receive Tentative FDA Approval

XuanTai Pharmaceutical's High-end Generic Drugs Approved for Sale in Multiple Countries

XuanTai Pharmaceutical Responds to Tariff Impact: Actively Expanding International Markets

SINOTHERAPEUTICS released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 108.93 M, actual EPS CNY 0.05

SINOTHERAPEUTICS to Release FY2025 Q1 Earnings on April 30 After-Market BJT

SINOTHERAPEUTICS FY2024 Annual Earnings Release on April 30 After-Market BJT

Shareholder of Xuantai Pharmaceutical Reduces Shares by 11 Million

688247

According to the Zhitong Finance APP, SINOTHERAPEUTICS disclosed its third-quarter report for 2025. The company achieved revenue of 331 million yuan in the first three quarters, a year-on-year decrease of 8.59%; the net profit attributable to the parent company was 63.46 million yuan, a year-on-year decrease of 31.45%; the net profit excluding non-recurring gains and losses was 53.88 million yuan, a year-on-year decrease of 36.64%; the basic earnings per share were 0.14 yuan

Zhitong

SINOTHERAPEUTICS released its performance for the first three quarters, with a net profit attributable to the parent company of 63.46 million yuan, a year-on-year decrease of 31.45%

SINOTHERAPEUTICS announced that recently, the company participated in the bidding organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. According to the "Proposed Selection Results Announcement for National Centralized Drug Procurement" released by the procurement office on October 28, 2025, the company's product Olaparib tablets is proposed to be selected for this centralized procurement

SINOTHERAPEUTICS: The company's products are expected to be selected for the national centralized procurement of drugs

SINOTHERAPEUTICS announced that its generic drug application for Sitagliptin Metformin Extended-Release Tablets has received temporary approval from the U.S. FDA. The drug was developed by MERCK SHARPDOHME and is used to improve blood sugar control in adults with type 2 diabetes

SINOTHERAPEUTICS: The Sitagliptin Metformin Extended-Release Tablets have received approval from the U.S. FDA

On September 30, 2025, the board of directors of Shanghai SINOTHERAPEUTICS Co., Ltd. received a written resignation letter from Vice President Wu Huafeng. Wu Huafeng applied to resign from the position of Vice President for personal reasons, with the original term set to end on May 30, 2026. After resigning, he will no longer hold any position in the company. His resignation will take effect from the date it is delivered to the board of directors, and the handover has been completed, ensuring that his departure will not affect the normal operation and management of the company

Wu Huafeng, Deputy General Manager of Shanghai SINOTHERAPEUTICS, has resigned early for personal reasons

SINOTHERAPEUTICS announced that its wholly-owned subsidiary Jiangsu Xuantai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the new specification of Sitagliptin Metformin Sustained-Release Tablets (each tablet contains 50mg of Sitagliptin and 500mg of Metformin Hydrochloride) to be used for the combination treatment of adult patients with type 2 diabetes

SINOTHERAPEUTICS: New specifications for Sitagliptin Metformin Extended-Release Tablets approved

300595

002657

On August 25th, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 3.883 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Zhongke Jincai 002657 Equity Incentive Restricted Circulation 1.2562 million AUTEK 300595 Equity Incentive Restricted Circulation 525,300 United Chemical 301209 Pre-issue Shares Restricted Circulation 55.5 million SINOTHERAPEUTICS 688247 3.11 billion DiAo Wei 688381 800 million Wantai Lingwei 688591 240 million

AUTEK

SINODATA

Zhitong A-share lock-up release overview | August 25

688439

688005

Next week, 31 stocks will have their restrictions lifted. Based on the latest closing prices, the total market value of the lifted restrictions amounts to 23.481 billion yuan. Ronbay Technology will have 250 million shares listed for circulation next week, mainly consisting of the original shareholders' restricted shares from the initial public offering, with a market value of 5.707 billion yuan. GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR follows with a lifting scale of 86 million shares listed for circulation next week, primarily consisting of the original shareholders' restricted shares from the initial public offering, with a market value of 5.282 billion yuan. In terms of the lifting ratio, SINOTHERAPEUTICS has the highest lifting ratio at 68.61%, followed by GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR, Ronbay Technology, and Kaige Precision Machinery

GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR

Ronbay Technology

31 stocks will face lifting of restrictions next week

SINOTHERAPEUTICS announced that in the first half of 2025, the operating income was 220 million yuan, a year-on-year increase of 0.74%. The net profit was 45.5857 million yuan, a year-on-year decrease of 15.82%. The company plans to distribute a cash dividend of 0.25 yuan for every 10 shares to all shareholders, with a total cash dividend distribution of 11.2251 million yuan, accounting for 24.62% of the net profit attributable to the parent company's shareholders for the period from January to June 2025

SINOTHERAPEUTICS: Net profit of 45.5857 million yuan in the first half of 2025, a year-on-year decrease of 15.82%

On the evening of August 17th, SINOTHERAPEUTICS announced that based on confidence in the company's future development prospects and recognition of the company's long-term value, as well as to enhance the confidence of a wide range of investors and effectively safeguard investor rights and the stability of the capital market, the company's controlling shareholder, Lianhe Investment, voluntarily committed not to reduce its holdings of the company's shares through centralized bidding, block trading, and other means for 24 months starting from August 25, 2025

SINOTHERAPEUTICS: The controlling shareholder Lianhe Investment voluntarily commits not to reduce its holdings in the company within 2 years

SINOTHERAPEUTICS's wholly-owned subsidiary, Jiangsu SINOTHERAPEUTICS Pharmaceutical Co., Ltd., recently received GMP certification from the European Medicines Agency (EMA). This is another significant achievement following its certifications from multiple national drug regulatory authorities, including China's NMPA, the U.S. FDA, Japan's PMDA, and Saudi Arabia's SFDA. It signifies that the company's quality system is aligned with international standards, helping to expand overseas markets, enhance market competitiveness, and support the company in providing R&D and production services to global pharmaceutical and biotechnology companies

SINOTHERAPEUTICS subsidiary Xuantai Pharmaceutical has passed the EU GMP certification

SINOTHERAPEUTICS(688247.SH)